The α-Synuclein Seeding Amplification Assay for Parkinson’s Disease
International Journal of Molecular Sciences · 04.01.2025 · 26 (1) · 389
DOI: 10.3390/ijms26010389 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 04.01.2025. Verfasst von Ling-Xiao Yi und 2 weiteren Autor:innen. Beteiligte Einrichtung: National Neuroscience Institute of Singapore, 11 Jalan Tan Tock Seng, Singapore 30843, Singapore. Hauptthemen laut MEDLINE: Parkinson Disease, alpha-Synuclein. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 92 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NMRC, Duke-NUS Medical School, Singapore National Medical Research Council (NMRC).
Abstract (Originalsprache)
Parkinson’s disease (PD) is the second most common neurodegenerative disease in the world. Currently, PD is incurable, and the diagnosis of PD mainly relies on clinical manifestations. The central pathological event in PD is the abnormal aggregation and deposition of misfolded α-synuclein (α-Syn) protein aggregates in the Lewy body (LB) in affected brain areas. Behaving as a prion-like seeding, the misfolded α-syn protein can induce and facilitate the aggregation of native unfolded α-Syn protein to aggravate α-Syn protein aggregation, leading to PD progression. Recently, in a blood-based α-Syn seeding amplification assay (SAA), Kluge et al. identified pathological α-Syn seeding activity in PD patients with Parkin (PRKN) gene variants. Additionally, pathological α-syn seeding activity was also identified in sporadic PD and PD patients with Leucine-rich repeat kinase 2 (LRRK2) or glucocerebrosidase (GBA) gene variants. Principally, the α-Syn SAA can be used to detect pathological α-Syn seeding activity, which will significantly enhance PD diagnosis, progression monitoring, prognosis prediction, and anti-PD therapy. The significance and future strategies of α-Syn SAA protocol are highlighted and proposed, whereas challenges and limitations of the assay are discussed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- National Neuroscience Institute of Singapore, 11 Jalan Tan Tock Seng, Singapore 30843, Singapore.
- Department of Neurology, Singapore General Hospital, Outram Road, Singapore 169608, Singapore.
- Signature Research Program in Neuroscience and Behavioral Disorders, Duke-NUS Graduate Medical School Singapore, 8 College Road, Singapore 169857, Singapore.
ORCID-Profile: Ling-Xiao Yi, Zhi Dong Zhou
Förderung
- NMRC
- Duke-NUS Medical School
- Singapore National Medical Research Council (NMRC)
- STaR
- CS-IRG
- OF-IRG
- HLCA
- Duke-Duke-NUS Collaboration Pilot Grant
Zitieren
APA
Yi, L. X., Tan, E. K., & Zhou, Z. D. (2025). The α-Synuclein Seeding Amplification Assay for Parkinson’s Disease. International Journal of Molecular Sciences, 26(1), 389. https://doi.org/10.3390/ijms26010389
Vancouver
Yi LX, Tan EK, Zhou ZD. The α-Synuclein Seeding Amplification Assay for Parkinson’s Disease. International Journal of Molecular Sciences. 2025;26(1):389. doi:10.3390/ijms26010389
BibTeX
@article{Yi2025,
author = {Yi, Ling-Xiao and Tan, Eng King and Zhou, Zhi Dong},
title = {The α-Synuclein Seeding Amplification Assay for Parkinson’s Disease},
journal = {International Journal of Molecular Sciences},
year = {2025},
volume = {26},
number = {1},
pages = {389},
doi = {10.3390/ijms26010389}
}
EUVIMED